ADMA Biologics (ADMA) Stock Forecast, Price Target & Predictions
ADMA Stock Forecast
ADMA Biologics stock forecast is as follows: an average price target of $9.25 (represents a -52.12% downside from ADMA’s last price of $19.32) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
ADMA Price Target
The average price target for ADMA Biologics (ADMA) is $9.25 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $14.00 to $4.50. This represents a potential -52.12% downside from ADMA's last price of $19.32.
ADMA Analyst Ratings
According to 3 Wall Street analysts, ADMA Biologics's rating consensus is 'Buy'. The analyst rating breakdown for ADMA stock is 1 'Strong Buy' (33.33%), 2 'Buy' (66.67%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
ADMA Biologics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 20, 2024 | Anthony Petrone | Mizuho Securities | $14.00 | $10.62 | 31.83% | -27.54% |
| Jan 03, 2023 | - | H.C. Wainwright | $4.50 | $3.88 | 15.98% | -76.71% |
| Nov 10, 2022 | - | Mizuho Securities | $6.00 | $3.05 | 96.68% | -68.94% |
| Jul 25, 2022 | - | H.C. Wainwright | $4.00 | $2.17 | 84.33% | -79.30% |
The latest ADMA Biologics stock forecast, released on Jun 20, 2024 by Anthony Petrone from Mizuho Securities, set a price target of $14.00, which represents a 31.83% increase from the stock price at the time of the forecast ($10.62), and a -27.54% decrease from ADMA last price ($19.32).
ADMA Biologics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $14.00 | $14.00 |
| Last Closing Price | $19.32 | $19.32 | $19.32 |
| Upside/Downside | -100.00% | -27.54% | -27.54% |
In the current month, the average price target of ADMA Biologics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to ADMA Biologics's last price of $19.32. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 12, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jul 09, 2024 | Cantor Fitzgerald | Overweight | Overweight | Hold |
| May 10, 2024 | Raymond James | Strong Buy | Strong Buy | Hold |
| May 10, 2024 | Cantor Fitzgerald | Overweight | Overweight | Hold |
| May 10, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Feb 29, 2024 | Cantor Fitzgerald | Underperform | Underperform | Hold |
| Feb 29, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jan 22, 2024 | Cantor Fitzgerald | Underperform | Underperform | Hold |
| Jan 22, 2024 | H.C. Wainwright | Buy | Buy | Hold |
ADMA Biologics's last stock rating was published by H.C. Wainwright on Aug 12, 2024. The company gave ADMA a "Buy" rating, the same as its previous rate.
ADMA Biologics Financial Forecast
ADMA Biologics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $67.27M | $60.12M | $56.91M | $49.98M | $41.09M | - | $29.10M | $26.38M | $20.68M | $17.83M | $16.05M | $13.96M | $10.28M | $7.79M | $10.20M | $12.04M | $7.22M | $6.56M | $3.53M | $4.23M | $4.66M |
| Avg Forecast | $119.04M | $116.66M | $114.31M | $111.17M | $110.69M | $105.84M | $86.44M | $77.28M | $72.13M | $62.13M | $55.50M | $51.26M | $46.35M | $34.48M | $31.81M | $25.90M | $21.76M | $18.70M | $16.42M | $14.58M | $12.85M | $9.96M | $10.57M | $11.34M | $10.42M | $5.77M | $4.08M | $3.48M | $3.97M | $4.12M |
| High Forecast | $120.75M | $118.35M | $115.96M | $112.78M | $112.29M | $106.09M | $87.68M | $78.39M | $73.17M | $63.02M | $56.30M | $52.00M | $47.02M | $34.98M | $31.81M | $26.44M | $22.21M | $19.09M | $16.76M | $14.88M | $13.12M | $10.17M | $10.79M | $11.58M | $10.64M | $5.89M | $4.16M | $3.55M | $4.77M | $4.95M |
| Low Forecast | $116.15M | $113.83M | $111.54M | $108.48M | $108.01M | $105.59M | $84.34M | $75.40M | $70.38M | $60.62M | $54.15M | $50.02M | $45.23M | $33.65M | $31.81M | $25.36M | $21.31M | $18.31M | $16.08M | $14.28M | $12.58M | $9.76M | $10.35M | $11.11M | $10.21M | $5.65M | $3.99M | $3.41M | $3.18M | $3.30M |
| # Analysts | - | - | - | - | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | 1 | 2 | 2 | 2 | 7 | 10 | 10 | 10 | 10 | 6 | 6 | 6 | 6 | 15 | 15 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.08% | 1.08% | 1.11% | 1.08% | 1.19% | - | 1.12% | 1.21% | 1.11% | 1.09% | 1.10% | 1.09% | 1.03% | 0.74% | 0.90% | 1.15% | 1.25% | 1.61% | 1.01% | 1.06% | 1.13% |
ADMA Biologics's average Quarter revenue forecast for Dec 23 based on 2 analysts is $72.13M, with a low forecast of $70.38M, and a high forecast of $73.17M. ADMA's average Quarter revenue forecast represents a 7.21% increase compared to the company's last Quarter revenue of $67.27M (Sep 23).
ADMA Biologics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | 1 | 2 | 2 | 2 | 7 | 10 | 10 | 10 | 10 | 6 | 6 | 6 | 6 | 15 | 15 |
| EBITDA | - | - | - | - | - | - | - | - | - | $8.69M | $2.03M | $-494.49K | $-6.32M | $-7.46M | - | $-13.36M | $-11.82M | $-12.99M | $-14.33M | $-13.95M | $-15.07M | $-12.79M | $-16.23M | $-15.74M | $-7.00M | $-7.97M | $-10.33M | $-10.72M | $-12.89M | $-12.54M |
| Avg Forecast | $-67.94M | $-66.58M | $-65.24M | $-63.45M | $-63.17M | $-60.41M | $-49.33M | $-7.22M | $-41.16M | $-35.46M | $-31.68M | $-7.72M | $-26.46M | $-16.20M | $-18.16M | $-8.26M | $-12.42M | $-14.72M | $-14.33M | $-14.78M | $-7.33M | $-12.79M | $-10.04M | $-14.52M | $-5.95M | $-9.36M | $-11.76M | $-12.06M | $-12.05M | $-10.92M |
| High Forecast | $-66.29M | $-64.97M | $-63.66M | $-61.91M | $-61.64M | $-60.27M | $-48.14M | $-5.78M | $-40.17M | $-34.60M | $-30.91M | $-6.18M | $-25.81M | $-12.96M | $-18.16M | $-6.61M | $-12.16M | $-11.78M | $-11.47M | $-11.82M | $-7.18M | $-10.23M | $-8.03M | $-11.62M | $-5.83M | $-7.49M | $-9.41M | $-9.65M | $-9.64M | $-8.74M |
| Low Forecast | $-68.92M | $-67.54M | $-66.18M | $-64.37M | $-64.09M | $-60.55M | $-50.04M | $-8.67M | $-41.76M | $-35.97M | $-32.13M | $-9.27M | $-26.84M | $-19.44M | $-18.16M | $-9.91M | $-12.68M | $-17.67M | $-17.20M | $-17.73M | $-7.49M | $-15.35M | $-12.05M | $-17.42M | $-6.07M | $-11.23M | $-14.11M | $-14.47M | $-14.47M | $-13.11M |
| Surprise % | - | - | - | - | - | - | - | - | - | -0.24% | -0.06% | 0.06% | 0.24% | 0.46% | - | 1.62% | 0.95% | 0.88% | 1.00% | 0.94% | 2.05% | 1.00% | 1.62% | 1.08% | 1.18% | 0.85% | 0.88% | 0.89% | 1.07% | 1.15% |
2 analysts predict ADMA's average Quarter EBITDA for Dec 23 to be $-41.16M, with a high of $-40.17M and a low of $-41.76M. This is -573.96% lower than ADMA Biologics's previous annual EBITDA (Sep 23) of $8.69M.
ADMA Biologics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | 1 | 2 | 2 | 2 | 7 | 10 | 10 | 10 | 10 | 6 | 6 | 6 | 6 | 15 | 15 |
| Net Income | - | - | - | - | - | - | - | - | - | $2.57M | $-6.37M | $-12.76M | $-25.93M | $-20.48M | - | $-35.20M | $-20.11M | $-20.99M | $-22.23M | $-21.60M | $-21.60M | $-20.03M | $-23.23M | $-21.72M | $-13.30M | $-13.83M | $-15.09M | $-12.93M | $-16.48M | $-16.08M |
| Avg Forecast | $42.78M | $41.17M | $39.55M | $37.13M | $35.11M | $31.48M | $19.37M | $-9.02M | $6.05M | $-1.82M | $-6.05M | $-9.65M | $-16.95M | $-22.08M | $-18.91M | $-10.32M | $-20.95M | $-20.07M | $-18.91M | $-19.46M | $-37.28M | $-16.92M | $-12.49M | $-17.75M | $-39.26M | $-13.43M | $-15.03M | $-14.70M | $-14.16M | $-12.84M |
| High Forecast | $43.59M | $41.94M | $40.30M | $37.83M | $35.77M | $32.07M | $19.74M | $-7.21M | $9.08M | $-1.76M | $-5.86M | $-7.72M | $-16.42M | $-17.67M | $-18.91M | $-8.25M | $-20.38M | $-16.06M | $-15.12M | $-15.57M | $-36.28M | $-13.53M | $-9.99M | $-14.20M | $-38.20M | $-10.74M | $-12.03M | $-11.76M | $-11.33M | $-10.28M |
| Low Forecast | $41.43M | $39.87M | $38.31M | $35.96M | $34.01M | $30.49M | $18.76M | $-10.82M | $3.03M | $-1.85M | $-6.17M | $-11.57M | $-17.27M | $-26.50M | $-18.91M | $-12.38M | $-21.51M | $-24.09M | $-22.69M | $-23.35M | $-38.29M | $-20.30M | $-14.98M | $-21.31M | $-40.32M | $-16.11M | $-18.04M | $-17.64M | $-16.99M | $-15.41M |
| Surprise % | - | - | - | - | - | - | - | - | - | -1.41% | 1.05% | 1.32% | 1.53% | 0.93% | - | 3.41% | 0.96% | 1.05% | 1.18% | 1.11% | 0.58% | 1.18% | 1.86% | 1.22% | 0.34% | 1.03% | 1.00% | 0.88% | 1.16% | 1.25% |
ADMA Biologics's average Quarter net income forecast for Dec 23 is $6.05M, with a range of $3.03M to $9.08M. ADMA's average Quarter net income forecast represents a 136.03% increase compared to the company's last Quarter net income of $2.57M (Sep 23).
ADMA Biologics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | 1 | 2 | 2 | 2 | 7 | 10 | 10 | 10 | 10 | 6 | 6 | 6 | 6 | 15 | 15 |
| SG&A | - | - | - | - | - | - | - | - | - | $14.73M | $14.25M | $14.51M | $13.89M | $12.89M | - | $13.70M | $11.70M | $10.73M | $10.44M | $10.03M | $9.30M | $9.12M | $8.70M | $7.93M | $7.03M | $7.20M | $6.09M | $5.60M | $5.36M | $5.01M |
| Avg Forecast | $67.34M | $66.00M | $64.67M | $62.89M | $62.62M | $59.87M | $48.90M | $4.94M | $40.80M | $35.14M | $31.40M | $5.28M | $26.22M | $13.37M | $18.00M | $5.65M | $12.31M | $12.16M | $10.44M | $10.62M | $7.27M | $9.12M | $5.38M | $7.32M | $5.90M | $3.26M | $2.31M | $1.97M | $2.25M | $2.33M |
| High Forecast | $68.31M | $66.95M | $65.60M | $63.80M | $63.52M | $60.01M | $49.60M | $5.93M | $41.39M | $35.65M | $31.85M | $6.34M | $26.60M | $16.05M | $18.00M | $6.78M | $12.56M | $14.59M | $12.53M | $12.75M | $7.42M | $10.94M | $6.46M | $8.78M | $6.02M | $3.33M | $2.35M | $2.01M | $2.70M | $2.80M |
| Low Forecast | $65.71M | $64.40M | $63.10M | $61.37M | $61.10M | $59.74M | $47.71M | $3.95M | $39.81M | $34.29M | $30.64M | $4.23M | $25.59M | $10.70M | $18.00M | $4.52M | $12.05M | $9.73M | $8.35M | $8.50M | $7.12M | $7.29M | $4.31M | $5.85M | $5.77M | $3.20M | $2.26M | $1.93M | $1.80M | $1.87M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.42% | 0.45% | 2.75% | 0.53% | 0.96% | - | 2.42% | 0.95% | 0.88% | 1.00% | 0.94% | 1.28% | 1.00% | 1.62% | 1.08% | 1.19% | 2.20% | 2.64% | 2.84% | 2.38% | 2.15% |
ADMA Biologics's average Quarter SG&A projection for Dec 23 is $40.80M, based on 2 Wall Street analysts, with a range of $39.81M to $41.39M. The forecast indicates a 177.08% rise compared to ADMA last annual SG&A of $14.73M (Sep 23).
ADMA Biologics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | 1 | 2 | 2 | 2 | 7 | 10 | 10 | 10 | 10 | 6 | 6 | 6 | 6 | 15 | 15 |
| EPS | - | - | - | - | - | - | - | - | - | $0.01 | $-0.03 | $-0.06 | $-0.13 | $-0.10 | - | $-0.18 | $-0.11 | $-0.16 | $-0.17 | $-0.19 | $-0.22 | $-0.23 | $-0.27 | $-0.29 | $-0.22 | $-0.23 | $-0.29 | $-0.28 | $-0.36 | $-0.38 |
| Avg Forecast | $0.18 | $0.17 | $0.16 | $0.15 | $0.14 | $0.13 | $0.08 | $0.06 | $0.03 | $-0.01 | $-0.03 | $-0.04 | $-0.07 | $-0.08 | $-0.08 | $-0.09 | $-0.09 | $-0.14 | $-0.15 | $-0.17 | $-0.17 | $-0.19 | $-0.16 | $-0.11 | $-0.17 | $-0.21 | $-0.28 | $-0.29 | $-0.29 | $-0.27 |
| High Forecast | $0.18 | $0.17 | $0.17 | $0.16 | $0.15 | $0.13 | $0.08 | $0.06 | $0.04 | $-0.01 | $-0.02 | $-0.04 | $-0.07 | $-0.08 | $-0.08 | $-0.08 | $-0.09 | $-0.13 | $-0.15 | $-0.16 | $-0.16 | $-0.18 | $-0.15 | $-0.11 | $-0.17 | $-0.21 | $-0.27 | $-0.28 | $-0.23 | $-0.22 |
| Low Forecast | $0.17 | $0.16 | $0.16 | $0.15 | $0.14 | $0.13 | $0.08 | $0.05 | $0.01 | $-0.01 | $-0.03 | $-0.04 | $-0.07 | $-0.08 | $-0.08 | $-0.09 | $-0.10 | $-0.14 | $-0.16 | $-0.17 | $-0.17 | $-0.19 | $-0.16 | $-0.12 | $-0.18 | $-0.22 | $-0.29 | $-0.30 | $-0.35 | $-0.32 |
| Surprise % | - | - | - | - | - | - | - | - | - | -1.52% | 1.14% | 1.35% | 1.86% | 1.29% | - | 2.12% | 1.19% | 1.16% | 1.11% | 1.15% | 1.33% | 1.23% | 1.72% | 2.54% | 1.27% | 1.08% | 1.04% | 0.97% | 1.24% | 1.41% |
According to 2 Wall Street analysts, ADMA Biologics's projected average Quarter EPS for Dec 23 is $0.03, with a low estimate of $0.01 and a high estimate of $0.04. This represents a 119.30% increase compared to ADMA previous annual EPS of $0.01 (Sep 23).
ADMA Biologics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| FATE | Fate Therapeutics | $3.88 | $39.75 | 924.48% | Buy |
| ANTX | AN2 Therapeutics | $1.06 | $8.75 | 725.47% | Buy |
| XFOR | X4 Pharmaceuticals | $0.70 | $3.67 | 424.29% | Buy |
| AKBA | Akebia Therapeutics | $1.35 | $6.50 | 381.48% | Buy |
| INMB | INmune Bio | $5.19 | $22.00 | 323.89% | Buy |
| PLRX | Pliant Therapeutics | $12.50 | $39.71 | 217.68% | Buy |
| ANEB | Anebulo Pharmaceuticals | $2.00 | $6.00 | 200.00% | Buy |
| SANA | Sana Bio | $4.29 | $12.00 | 179.72% | Buy |
| ETNB | 89bio | $8.31 | $22.00 | 164.74% | Buy |
| VXRT | Vaxart | $0.90 | $2.00 | 122.22% | Hold |
| STOK | Stoke Therapeutics | $15.22 | $33.75 | 121.75% | Buy |
| RCUS | Arcus Biosciences | $16.49 | $35.20 | 113.46% | Buy |
| CDTX | Cidara Therapeutics | $11.62 | $24.00 | 106.54% | Buy |
| BCRX | BioCryst Pharmaceuticals | $7.96 | $16.00 | 101.01% | Buy |
| CRBU | Caribou Biosciences | $2.08 | $3.00 | 44.23% | Buy |
| MDGL | Madrigal Pharmaceuticals | $233.16 | $315.75 | 35.42% | Buy |
| ATRA | Atara Biotherapeutics | $7.87 | $10.50 | 33.42% | Sell |
| MCRB | Seres Therapeutics | $1.05 | $1.25 | 19.05% | Buy |
| ACLX | Arcellx | $80.55 | $61.00 | -24.27% | Buy |
| ADMA | ADMA Biologics | $19.32 | $9.25 | -52.12% | Buy |
ADMA Forecast FAQ
Is ADMA Biologics a good buy?
Yes, according to 3 Wall Street analysts, ADMA Biologics (ADMA) is considered a 'Buy'. The rating consensus is based on 1 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of ADMA's total ratings.
What is ADMA's price target?
ADMA Biologics (ADMA) average price target is $9.25 with a range of $4.5 to $14, implying a -52.12% from its last price of $19.32. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will ADMA Biologics stock go up soon?
According to Wall Street analysts' prediction for ADMA stock, the company can go down by -52.12% (from the last price of $19.32 to the average price target of $9.25), down by -27.54% based on the highest stock price target, and down by -76.71% based on the lowest stock price target.
Can ADMA Biologics stock reach $30?
ADMA's average twelve months analyst stock price target of $9.25 does not support the claim that ADMA Biologics can reach $30 in the near future.
What are ADMA Biologics's analysts' financial forecasts?
ADMA Biologics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $380.24M (high $384.45M, low $373.34M), average EBITDA is $-180M (high $-176M, low $-183M), average net income is $76.95M (high $80.37M, low $72.44M), average SG&A $176.33M (high $179.07M, low $172.5M), and average EPS is $0.41 (high $0.418, low $0.397). ADMA's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $461.19M (high $467.84M, low $450M), average EBITDA is $-263M (high $-257M, low $-267M), average net income is $160.64M (high $163.65M, low $155.57M), average SG&A $260.9M (high $264.67M, low $254.57M), and average EPS is $0.663 (high $0.676, low $0.642).
Did the ADMA's actual financial results beat the analysts' financial forecasts?
Based on ADMA Biologics's last annual report (Dec 2023), the company's revenue was $258.22M, beating the average analysts forecast of $241.01M by 7.14%. Apple's EBITDA was $21.63M, missing the average prediction of $-116M by -118.64%. The company's net income was $-28.239M, beating the average estimation of $-11.461M by 146.38%. Apple's SG&A was $59.02M, missing the average forecast of $112.63M by -47.60%. Lastly, the company's EPS was $-0.0001, missing the average prediction of $-0.05 by -99.80%. In terms of the last quarterly report (Sep 2023), ADMA Biologics's revenue was $67.27M, beating the average analysts' forecast of $62.12M by 8.29%. The company's EBITDA was $8.69M, missing the average prediction of $-35.457M by -124.50%. ADMA Biologics's net income was $2.57M, missing the average estimation of $-1.816M by -241.23%. The company's SG&A was $14.73M, missing the average forecast of $35.14M by -58.10%. Lastly, the company's EPS was $0.0114, missing the average prediction of $-0.0075 by -252.00%